Abstract
Background: The ability to predict patients with stage II colon cancer at high risk of recurrence
is currently limited to certain clinicopathologic factors. Patients and Methods: This population-based study reviewed various prognostic factors to identify those
associated with worse time to recurrence (TTR) and improved disease-specific survival
(DSS), and to subsequently develop a prognostic index (PI) to identify high risk cancers.
Results: Multivariate analyses revealed factors significant for TTR and DSS. A PI derived
from the TTR risk factors identified 3 risk groups using 5-year rate without relapse:
88% for low-risk, 81% for intermediate-risk, and 59% for high risk. Conclusion: This model was better at identifying high risk patients than using equally weighted
standard risk factors.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Colorectal CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set.J Clin Oncol. 2008; 26: 2336-2341https://doi.org/10.1200/JCO.2007.15.8261
- Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.J Clin Oncol. 2009; 27: 872-877https://doi.org/10.1200/JCO.2008.19.5362
- American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer.J Clin Oncol. 2004; 22: 3408-3419https://doi.org/10.1200/JCO.2004.05.063
- Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.J Clin Oncol. 2013; 31: 1775-1781https://doi.org/10.1200/JCO.2012.45.1096; 10.1200/JCO.2012.45.1096
- Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?.J Clin Oncol. 2004; 22: 1797-1806https://doi.org/10.1200/JCO.2004.09.059
- Adjuvant chemotherapy for stage II colon cancer with poor prognostic features.J Clin Oncol. 2011; 29: 3381-3388https://doi.org/10.1200/JCO.2010.34.3426; 10.1200/JCO.2010.34.3426
- Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial.J Clin Oncol. 2012; 30: 3353-3360https://doi.org/10.1200/JCO.2012.42.5645; 10.1200/JCO.2012.42.5645
- Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer.Cancer. 2015; 121: 527-534https://doi.org/10.1002/cncr.29072
- Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer.Cancer. 2016; 122: 3277-3287https://doi.org/10.1002/cncr.30181
- Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.J Clin Oncol. 2013; 31: 4512-4519https://doi.org/10.1200/JCO.2012.47.3116
- Association between results of a gene expression signature assay and recurrence-free interval in patients with stage II colon cancer in cancer and leukemia group B 9581 (alliance).J Clin Oncol. 2016; 34: 3047-3053https://doi.org/10.1200/JCO.2015.65.4699
- Tutorial in biostatistics: multivariable prognostic models.Stat Med. 1996; 15: 361-387
- Estimating Harrell's Optimism on Predictive Indices Using Bootstrap Samples.SAS Global Forum, 2013
- Chapter 8 prognostic indices.Survival Analysis: A practical Approach. 2nd ed. John Wiley and Sons, West Sussex, England2006
- The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.Ann Surg Oncol. 2010; 17: 1471-1474https://doi.org/10.1245/s10434-010-0985-4
- Prognostic effect of sidedness in early stage versus advanced colon cancer.Health Sci Rep. 2018; 1: e54https://doi.org/10.1002/hsr2.54
- Prognostic effect of tumor sidedness in colorectal cancer: a SEER-based analysis.Clin Colorectal Cancer. 2019; 18 (S1533-0028(18)30456-0): e104-e116
- Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.Sci Transl Med. 2016; 6 (8346ra92)https://doi.org/10.1126/scitranslmed.aaf6219
- Differences between referred and nonreferred patients in cancer research.Can J Surg. 2013; 56: E135-E141https://doi.org/10.1503/cjs.027511
Article info
Publication history
Published online: October 02, 2021
Accepted:
September 9,
2021
Received in revised form:
August 6,
2021
Received:
March 7,
2021
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
